Investisbest I don't think it means anything that Duke joined the ADXS FB opinion group as Bonstein and Mayes are also on it. The tea leaves i am reading into is Dans comment in the recent interview that our most advanced construct AXAL should work well with Keytruda/Merck and Dumurab/Astra. He mentioned Merck first but the only trial currently with Merck is on PSA for prostate, not AXAL. Maybe Merck is stepping up with a licensing deal with us for both PSA and AXAL if they like the trial data emerging with our PSA combo trial. Granted Astra has first right of refusal for AXAL combo licensing but considering Astra already has a 700m deal with INO on HPV cancers and they just expanded it could mean they are stepping aside for a Merck deal with ADXS.
News 
Market Data 
Discover 
